

Supplementary Material

Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort

Supplementary Table 1. Summary of clinical information at T1 and at last follow-up

	T1	Last clinical follow-up*	Deaths*
Diagnosis	Possible PD: n=47	Possible PD: n= 7 Probable PD: n= 38 PDD: n= 2	n=1
P symptoms' duration# (months)	28 (26-28)	64 (40-106)	
Diagnosis	Probable PD: n=37	Probable PD: n= 35 PDD: n= 2	n=2
P symptoms' duration# (months)	40 (40-52)	76 (52-100)	
Diagnosis	APs: n=16 PSP: n=3 MSA: n=5 DLB: n=2 CBS: n=2	APs: n=15 PDD: n= 1 PSP: n= 3 MSA: n= 5 DLB: n= 2 CBS: n= 2	n=9 n=3 n=3 n=1 n=2
P symptoms' duration# (months)	uAP: n=4 40 (40-43)	uAP: n= 2; PDD: n=1; DLB: n=1 60 (47-82)	

T1, 16-month follow-up; *at December 2018; #expressed as median (25-75 percentiles).

P, parkinsonian; PD, Parkinson's disease; PDD, PD with dementia; P, parkinsonian; AP, atypical parkinsonism; PSP, progressive supranuclear palsy; MSA, multiple system atrophy; DLB, dementia with Lewy bodies; CBS, corticobasal syndrome.

Supplementary Figure 1. Computerized touch screen system for alternate index finger tapping test (mHealth Technologies srl, Bologna, Italy)

